Treating COVID-19 with Chloroquine

Huang, Mingxing; Tang, Tiantian; Pang, Pengfei; Li, Man; Ma, Ruolan; Lu, Jiahui; Shu, Jingxian; You, Yingying; Chen, Binghui; Liang, Jing; Hong, Zhongsi; Chen, Huili; Kong, Ling; Qin, Dajiang; Pei, Duanqing; Xia, Jinyu; Jiang, Shanping; Shan, Hong

doi:10.1093/jmcb/mjaa014

Cited by 234 publications

(329 citation statements)

References 9 publications

Supporting

Mentioning

316

Contrasting

Unclassified

Order By: Relevance

“…Huang and colleagues [15] conducted a small pilot study in patients with Covid-19. A total of 22 patients were divided into two groups: one (n = 10) treated with chloroquine (500 mg, oral administration, twice daily) and another (n = 12) with lopinavir/ritonavir (400/100 mg, oral administration, twice daily) for 10 days and monitored for a total of 14 days.…”

Section: Data Supporting the Investigation Of Chloroquine In Covid-19mentioning

confidence: 99%

Covid-19 treatment update: follow the scientific evidence

Becker

2020

J Thromb Thrombolysis

View full text Add to dashboard Cite

Section: Data Supporting the Investigation Of Chloroquine In Covid-19mentioning

confidence: 99%

Covid-19 treatment update: follow the scientific evidence

Becker

2020

J Thromb Thrombolysis

View full text Add to dashboard Cite

“…In a pilot study (10) aiming to evaluate the efficacy and safety of chloroquine in inpatients with COVID-19, 10 patients (3 with severe disease and 7 with moderate disease) received chloroquine phosphate 500 mg orally twice a day for 10 days, and 12 patients (5 with severe disease and 7 with moderate disease) received lopinavir/ritonavir 400/100 mg orally twice a day for 10 days. Chloroquine was slightly superior to lopinavir/ ritonavir in terms of virus-negative conversion since the chloroquine group tested negative for SARS-CoV-2 at a slightly higher rate than the control group on day 7, day 10, and day 14 post-treatment (10).…”

mentioning

confidence: 99%

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)

Gao

2020

BST

View full text Add to dashboard Cite

“…Two studies (15,16) outline key information on socio-demographic and clinical characteristics; both used comparison groups to test the effectiveness of the drugs.…”

Section: Comparison With Existing Literaturementioning

confidence: 99%

Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review

Rawaf

Al-Saffar

Yamamoto

et al. 2020

Preprint

View full text Add to dashboard Cite

In a search to find effective treatments for COVID-19, chloroquine and hydroxychloroquine have gained attention. We aim to provide evidence to support clinical decision-making regarding medication for the treatment of COVID-19 by carrying out a systematic review of the literature. The electronic databases MEDLINE, EMBASE, Global Health, and HMIC were searched up to April 2020.Eligible study outcomes included: extubation or patient recovery. Relevant data were extracted and analysed by narrative synthesis. Our results included six studies in the review of which four studies were of good or fair quality. All eligible studies included were for coronavirus involving the use of either chloroquine or hydroxychloroquine to treat common symptoms such as fever, cough, shortness of breath and fatigue.Outcomes most commonly reported were improved lung function, viral clearance, and hospital discharge. Strong evidence to support the use of chloroquine and

show abstract

Treating COVID-19 with Chloroquine

Cited by 234 publications

References 9 publications

Covid-19 treatment update: follow the scientific evidence

Covid-19 treatment update: follow the scientific evidence

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)

Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review

Contact Info

Product

Resources

About